Emergent Biosolutions Inc (EBS)

NYSE
Currency in USD
7.330
+0.460(+6.70%)
Closed·
After Hours
7.260-0.070(-0.955%)
·

NYSE:EBS Financials

Key Ratios

P/E Ratio-2.6
Price/Book0.63
Debt / Equity121.71%
Return on Equity-21.63%
Dividend Yield0.00%
EBITDA53.40M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa1,577.31,773.61,117.51,049.31,043.6
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa863.1793.2473360375.4
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa499.2386-109.3-168.1-52.2
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa305.8219.5-211.6-760.5-190.6
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa2,883.22,957.73,166.31,823.21,389.7
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa384.53741,228.9651.3162.4
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa1,4471,611.51,387.7649.3482.8
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa393.9439.19-203.13-88.658.5
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa536.9320.2-34.1-206.358.7
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-151.9-224.1-381.3212.3125.2
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa69.5-141481.2-535.7-190
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa453.5-45.266.3-530.9-6.1
* In Millions of USD (except for per share items)

Analyst Ratings

2 Buy
0 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 13.500
(+84.17% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
0.71 / 0.49
Revenue / Forecast
222.20M / 279.00M
EPS Revisions
Last 90 days

FAQ

What were Emergent Biosolutions's earnings for the latest quarter?

The Emergent Biosolutions EPS (TTM) is -2.46. Emergent Biosolutions reported sales of The Emergent Biosolutions EPS (TTM) is -2.46. Emergent Biosolutions reported sales of 222.20, net income of 68.00, and EPS of 0.71 for the latest quarter., net income of 68.00, and EPS of 0.71 for the latest quarter.

What was Emergent Biosolutions's net income for the latest quarter?

Emergent Biosolutions's net income for the latest quarter was 68.00.

How did Emergent Biosolutions's performance compare year-over-year in the latest quarter?

The company's revenue moved from 194.70 in the previous quarter to 222.20 in the latest quarter, and net income moved from -31.30 to 68.00 compared to the previous quarter.

What is Emergent Biosolutions's net profit margin on a TTM basis?

Emergent Biosolutions's trailing twelve months (TTM) net profit margin is -18.26%.

How does Emergent Biosolutions's debt to equity ratio compare to industry standards?

Emergent Biosolutions's total debt-to-equity ratio is 121.71%.

What is Emergent Biosolutions's return on investment on a TTM basis?

Emergent Biosolutions's trailing twelve months (TTM) return on investment (ROI) is -21.63%.

Did Emergent Biosolutions gain or lose cash last quarter?

In the latest quarter, Emergent Biosolutions's net change in cash was 47.20 million.

What were Emergent Biosolutions's total assets and liabilities in the latest quarter?

As of the latest quarter, Emergent Biosolutions reported total assets of 1,426.10 million and total liabilities of 111.90 million.

How has Emergent Biosolutions's total revenue grown this year?

Emergent Biosolutions's total revenue was 194.70 in the previous quarter and 222.20 in the latest quarter.

What is Emergent Biosolutions's gross margin on a TTM basis?

Emergent Biosolutions's trailing twelve months (TTM) gross margin is 36.67%.

What was Emergent Biosolutions's revenue per share for the latest quarter?

Emergent Biosolutions's revenue per share for the latest quarter was 42.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.